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Background: The problem of emerging ciprofloxacin resistance is compounded by its frequent association with
multiresistance, the reason for which is not fully understood. In this study we compare multiresistance, clonal
similarities and phylogenetic group in urinary tract isolates of Escherichia coli sensitive and resistant to the
quinolone antimicrobials nalidixic acid and ciprofloxacin.
Results: Quinolone resistant isolates were more resistant to non-quinolone antibiotics than sensitive isolates, with
resistance to ampicillin, mecillinam, sulphonamide, trimethoprim, tetracycline, kanamycin and chloramphenicol
significantly increased. Fifty-one percent of quinolone-resistant isolates were multiresistant. Although multiresistance
was most prevalent (63%) in isolates showing high-level ciprofloxacin resistance, it was still highly prevalent (41%) in
nalidixic acid resistant isolates with low-level ciprofloxacin resistance. Multiresistance was more frequent among
singleton isolates (61%) than clonal isolates (40%) of quinolone resistant Escherichia coli. Ciprofloxacin resistance
was associated with certain specific clones, among them the globally distributed clonal Group A. However, there
was no significant difference in the overall degree of clonality between quinolone sensitive and resistant isolates.
Ciprofloxacin resistance was positively associated with phylogroup D and negatively associated with phylogroup
B2. This correlation was not associated with clonal isolates.
Conclusion: This study supports earlier findings of association between ciprofloxacin resistance and resistance
to other antibiotics. The prevalence of multiresistance in quinolone-resistant isolates that have not yet developed
high-level ciprofloxacin resistance suggest that multiresistance arises early in the development of quinolone resistance.
This is consistent with exposure to quinolones causing quinolone resistance by mutations and mobilization of
multiresistance elements by induction of the SOS response. The spread of clones seems to be less important than
previously reported in regard to emergence of quinolone resistance and multiresistance as both are associated
primarily with singleton isolates.
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Since the broad spectrum fluoroquinolone antibiotics were
introduced in clinical practice, fluoroquinolone resistant
E. coli (FQREC) strains have been isolated with increasing
frequency, with prevalence as high as 25 – 50% being
reported from some southern European countries. In* Correspondence: linda.strand@sthf.no
1Unilabs Telelab, Skien, Norway
3Department of Microbiology and Virology, University of Tromsø, Tromsø,
Norway
Full list of author information is available at the end of the article
© 2014 Strand et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Norway the prevalence of quinolone resistance, although
still low, has doubled to 9.7% in the period 2005 – 2009 [1].
Quinolone resistance is principally due to mutations in
the DNA gyrase gene gyrA. Single mutations result in
nalidixic acid resistance and moderately raised ciprofloxacin
resistance, while full resistance to ciprofloxacin requires
two gyrA mutations. Mutations in parC [2-4], mutations
that effect efflux pumps or cell permeability and plasmid-
borne factors may also contribute to resistance [5-7].
The problem of emerging ciprofloxacin resistance is
further compounded by its frequent association with
multiresistance to other antibiotics [8-13]. The reason forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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may be considered. Ciprofloxacin-resistant isolates have
been reported to show a high level of clonality [8,14] and
resistance has emerged in the multiresistant uropatho-
genic clonal group A (CGA) [15-20], which suggests a
contribution from the spread of multiresistant clones
under selection pressure. The agricultural sector has also
been suggested as a source of ciprofloxacin resistance
[21], in which case multiresistance might arise at source,
driven by the extensive use of antibiotic additives as
growth stimulants in animal feed. An association between
multiresistance and ciprofloxacin resistance might be
explained if ciprofloxacin tends to be chosen when
therapy with first-line preparations fails due to multire-
sistance in the target organism. Lastly, quinolones are
mutagenic and induce the SOS response which in turn
activates the mobility of transposable elements [22-24],
suggesting that chromosomal mutations and/or the spread
of mobile resistance factors might be involved.
In this study we investigate multiresistance and clonal
similarities in ciprofloxacin-sensitive and ciprofloxacin-
resistant urinary tract isolates of E. coli, as well as the
nalidixic-acid resistant isolates that are thought to be
their precursors. Our results suggest that multiresistance
emerges early in the development of ciprofloxacin resist-
ance and place constraints on several of the possible ex-
planations for association between ciprofloxacin resistance
and multiresistance. We also reinvestigate our earlier find-
ings suggesting fluoroquinolone resistance and clonal
spread and the emergence of fluoroquinolone resistance
in clonal group A [20].Results
Ciprofloxacin MIC distribution
Figure 1 shows the ciprofloxacin MIC distribution of the
isolates. The isolates are clearly separated into three sub-
populations with peak MICs of 0.032, 0.5 and 64 mg/L.
The first population consists of the nalidixic acid sensitive
isolates, while the second two contain the nalidixic acid
resistant isolates. We have chosen to divide our material
on the basis of the natural divisions between the three
subpopulations at 0.064 - 0.125 and 2–4 mg/L, rather than
the clinical breakpoints, which do not coincide with
the natural divisions in this material. In order to avoid
confusion with the established sensitive-intermediate-
resistant terminology, we refer to our three subpopula-
tions as Cipro0.032- nalidixic acid sensitive isolates with
ciprofloxacin MIC ≤ 0.064 and modal MIC 0.032 mg/L
(N = 43); Cipro0.5 – nalidixic acid resistant isolates with
ciprofloxacin MIC ≥ 0.125 and ≤ 2 and modal MIC
0.5 mg/L (N = 75) and Cipro64 – nalidixic acid resistant,
ciprofloxacin resistant isolates with ciprofloxacin MIC ≥ 4
and modal MIC 32–64 mg/L (N = 75). Cipro0.5 andCipro64 isolates are collectively referred to as nalidixic
acid resistant isolates.
Resistance to non-quinolone antibiotics
Nalidixic acid resistant isolates (Cipro0.5 and Cipro64) ex-
pressed a greater number of non-quinolone antibiotic
resistances (mean = 3.5) than nalidixic acid sensitive
(Cipro0.032) isolates (mean = 0.4; p < 0.001, t-test), with
resistance to all antibiotics tested except nitrofurantoin
significantly increased (z-test, p < 0.05). There was also a
slight, but significant difference in the number of resis-
tances between Cipro0.5 (mean = 3.2) and Cipro64 isolates
(mean = 3.8; p < 0.05), with significant increase in resist-
ance to trimethoprim and sulphonamide (z-test, p < 0.05).
Antibiotic resistances of the isolates are shown in Table 1.
Fifty-one percent (77/150) of the nalidixic acid resist-
ant isolates were multiresistant, as defined by resistance
to four classes of antibiotics in addition to quinolones;
17% (25/150) of the isolates were resistant to five, 6% (9/
150) to six and one to seven other antibiotic classes; this
isolate showed intermediate susceptibility to mecillinam
and was otherwise fully resistant to all antibiotics tested
including ciprofloxacin. Eight isolates were fully suscep-
tible only to nitrofurantoin.
Forty percent (30/75) of Cipro0.5 were multiresistant
and 63% (47/75) of Cipro64 were multiresistant as defined
by resistance to four classes of antibiotics in addition to
quinolones. Fourty-nine percent of isolates conforming
to the standard definition of ciprofloxacin resistance
(MIC ≥ 2 mg/L) were multiresistant.
18% (27/150) of the nalidixic acid resistant isolates shared
a distinctive ampicillin-chloramphenicol-sulphonamide-
tetracycline-trimethoprim multidrug resistance phenotype;
these were approximately equally distributed between
Cipro0.5 (56%) and Cipro64 (44%).
Only one nalidixic acid sensitive isolate was multiresistant.
Clonal distribution and phylogroup
Pulsed-field gel electrophoresis (PFGE) analysis identified
20 clones containing two to 12 isolates (Table 2, Figure 2).
Seventy-eight (43%) of the typable isolates were clonal and
105 (57%) were singletons. Ten isolates were non-typable
due to DNA degradation; these were excluded from statis-
tical analyses of clonal groups. All ten non-typable isolates
were of phylogenetic group D, resistant to nalidixic acid,
ciprofloxacin (MIC 32–64 mg/L) and sulphonamide and
lactose non-fermenting. Eight of these isolates were also
resistant to trimethoprim, and seven were resistant to
tetracycline and ampicillin. Five (50%) showed resistance
against four or more antibiotics in addition to quinolones.
The two largest clones, clones 1 and 2, contained 12
isolates each and represented 13% (24/183) of the mater-
ial. All clone 1 and 2 isolates were nalidixic acid resistant.













Cipro0.032 Cipro 0.5 Cipro
64
Figure 1 Trimodal distribution of ciprofloxacin MIC. Nalidixic acid sensitive isolates are shown in grey. Vertical lines delineate the subdivisions
used for analysis in the rest of the article. The arrow indicates the EUCAST breakpoint between clinical resistance and sensitivity [1].
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group A. All clones were homogeneous with respect to
phylogenetic group.
There was a significant association between clonality
and phylogenetic group (Chi-square = 8.850 with 3 degrees
of freedom; p = 0.040) (Figure 3). This can be attributed to
the greater prevalence of phylogroup B2 among clonal
isolates (+16% (CI95: 2-30%) p = 0.03, z-test) and of
phylogroup A among singleton isolates (+13% (CI95:2-
25%) p = 0.04, z-test). The proportion of phylogroup B1
and D was similar among clonal and singleton isolates
(Figure 3) and there was no significant difference in
clonality between these groups.Table 1 Antibiotic resistances
Cipro0.032 (n = 43) Cipro0.5 (n = 75) Cipro64 (n = 75)
Antibiotic S I R S I R S I R
Ampicillin - 37 6 - 22 53 - 16 59
Mecillinam 41 - 2 62 - 13 60 - 15
Kanamycin 42 - 1 66 - 9 61 - 14
Chloramphenicol 41 - 2 50 - 25 45 - 30
Tetracycline 38 - 5 27 1 47 19 3 53
Nitrofurantoin 43 - - 74 - 1 74 - 1
Sulphonamide 34 3 6 22 1 52 13 0 62
Trimethoprim 38 - 5 32 1 42 20 - 55
Cutoff values between sensitive, intermediate and resistant were: Ampicillin:
I >0.5, R >8; Mecillinam: R >8; Chloramphenicol: R >8; Nitrofurantoin: R >64;
Trimethoprim: I >2, R >4 [25]. Tetracycline: I >4, R >8; Sulphonamide: I >64,
R >128 [26]. Kanamycin: R >10.There were no significant differences in the degree of
clonality between Cipro0.032, Cipro0.5 and Cipro64 isolates
(Chi-square (2 d.f.) = 3.966, p = 0.138), or between nalidixic
acid sensitive and resistant isolates (Chi-square = 0.994;
P = 0.319), see Figure 4. Ciprofloxacin resistance was,
however, associated with specific clones. Two clones
contained only Cipro64 isolates; six contained only Cipro0.5
isolates and three contained only Cipro0.032 isolates; five
groups contained Cipro0.032 and Cipro0.5 isolates and four
contained Cipro0.5 and Cipro64 isolates; no clone contained
both Cipro0.032 and Cipro64 isolates (Table 2).
Clonal group A (CGA)
All twelve CGA isolates were resistant to nalidixic acid
with ciprofloxacin MICs from 0.25 to 8 mg/L, broadly
coincident with the Cipro0.5 distribution. Four were cip-
rofloxacin resistant (MIC ≥ 2 mg/L). Eight isolates were
multiresistant: four were resistant to four, three to five
and one to six other antibiotics. This last isolate was
fully sensitive only to nitrofurantoin.
Three isolates shared the ampicillin-chloramphenicol-
sulphonamide-tetracycline-trimethoprim multidrug resist-
ance phenotype predominant in other multiresistant
nalidixic acid resistant isolates.
Quinolone resistance and phylogroup
Ciprofloxacin resistance was positively associated with
phylogroup D and negatively associated with phylogroup
B2 (Figure 5). Phylogroup D was significantly more preva-
lent (44%, 33/75) among Cipro64 isolates than among
Cipro0.032 isolates (23%, 10/43) (+21%, CI95: 2%-38%;
Table 2 Ciprofloxacin resistance and phylogenetic groups
of clones
N Cipro0.032 Cipro0.5 Cipro64 Phylogroup
Clone 1 12 - 1 11 B2 Includes
outbreak
Clone 2 12 - 10 2 D CGA
Clone 3 7 - - 7 D
Clone 4 5 5 - - B2
Clone 5 6 - 6 - B2
Clone 6 4 1 3 - D
Clone 7 4 1 3 - B2
Clone 8 3 - 1 2 A
Clone 9 3 3 - - B1
Clone 10 2 - 2 - B2
Clone 11 2 - 2 - B2
Clone 12 2 - - 2 B1
Clone 13 2 1 1 - A
Clone 14 2 - 2 - B2
Clone 15 2 1 1 - B2
Clone 16 2 - 1 1 A
Clone 17 2 - 2 - A
Clone 18 2 2 - - D
Clone 19 2 1 1 - B2
Clone 20 2 - 2 - D
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was lower (21%, 16/75) in Cipro64 than in Cipro0.032
(56%, 24/43) (−35%, CI95: 17%-53%; z-test, p < 0.001).
In order to investigate whether this is due to the effect of
clones, we compared the correlation between phylogroup
and quinolone resistance in singleton and clonal isolates.
Phylogroup was correlated with quinolone resistance in
singleton isolates (chi-squared, 6 d.f. = 17.009, p = 0.009),
but not in clonal isolates (Chi-square, 6 d.f. = 8.626;
p = 0.196). Phylogroup B2 was 45% (CI95: 23%-67%)
less prevalent in Cipro64 than in Cipro0.032 singleton
isolates (p < 0.001, z-test); the prevalence of phylogroups
A, B1 and D was increased but did not achieve statistical
significance (p > 0.2, z-test).
Multiresistance in clonal and singleton isolates
In quinolone-resistant isolates, multiresistance, as defined
by resistance to four classes of non-quinolone antibiotics,
was found in 25 of 63 (40%) clonal isolates and 47/77
(61%) singleton isolates. This is statistically significant
(p = 0.019). Non-typable isolates were not included.
Discussion
This study supports earlier findings [8-13] of an associ-
ation between ciprofloxacin resistance and resistance toother antibiotics, frequently in the form of multiresistance.
Association was found with resistance to all antibiotics
tested except nitrofurantoin. This, however, applies not
only to ciprofloxacin-resistant isolates but also to nalidixic
acid resistant isolates with low ciprofloxacin resistance
levels, which may be presumed to be isolates with only
one gyrA mutation. This indicates that multiresistance
arises at an early stage in the stepwise development of cip-
rofloxacin resistance. As far as we are aware, association
between nalidixic acid resistance and multiresistance has
not previously been reported.
Eight quinolone-resistant isolates were susceptible only
to nitrofurantoin; one isolate showed only intermediate
susceptibility to mecillinam and was otherwise fully resist-
ant to all antibiotics tested. These isolates were not
clonally related. However, one isolate belonged to clonal
group A and resembled two highly resistant CGA isolates
previously isolated by us in 2003 [20].
The cause of the association between multiresistance
and quinolone resistance is not known. However, a model
based on spread of multiresistant clones is not consist-
ent with our data. If the emergence of multiresistant
quinolone-resistant isolates were due to clonal spread,
we would expect multiresistance to be more prevalent
among clonal isolates. This is the reverse of what we
observe in this study. Singleton isolates are significantly
more multiresistant than clonal isolates.
Neither do our results confirm previous findings of
increased clonality among ciprofloxacin-resistant isolates
[8,14]. Ciprofloxacin resistant isolates were no more clonal
than sensitive isolates. Ciprofloxacin resistant clones did
however occur, suggesting that clonal spread does make
some contribution to the spread of ciprofloxacin resistance.
Cagnacci et al. assigned 34% of 148 ciprofloxacin resistant
isolates to two clonal groups using a combination of
methods including multilocus sequence typing (MLST)
[14]. This is a higher degree of clonality than we observe,
despite their collection being both more geographically dis-
persed and collected over a longer time period. However
their study includes material from the Mediterranean region
where quinolone resistance is well established, while our
material is from a low-prevalence region where emergence
of quinolone resistance may still be dominant over spread.
Clonal group A was the second most prevalent clone
found in our material, representing 6% (12/193) of the
isolates. All CGA isolates were quinolone resistant and
one third were ciprofloxacin resistant, confirming the
emergence of fluoroquinolone resistance in CGA that we
[20] and others [11] have previously observed. Although
CGA is considered a multiresistant clone, CGA isolates in
this material were not significantly more multiresistant
than other quinolone resistant isolates (p > 0.5, z-test). In
2001, CGA comprised 19% of quinolone sensitive isolates,
while in this material, from 2005, quinolone-sensitive
13 16 15 10 8 17Clone 111
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Figure 2 XbaI PFGE patterns of the isolates. (a-e) Highlighting of the isolate code indicates cipro64 (red), cipro0.5 (yellow) and cipro0.032 (not
highlighted). Grey indicates that the sample is excluded from the study. Panels a - e are parts of a single image which has been divided for
convenience of presentation. The left border of panel a is the right border of panel b, and so forth. Clone numbers are placed between the
dendrogram and the gel pictures. In a few cases, patterns grouped with a clone in the dendrogram do not satisfy our criteria for clone inclusion
(<7 bands difference from the prototype). Therefore the number of patterns marked may differ from the number given in Table 2.
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cant (p = 0.011, z-test) and strongly suggests that a shift to
quinolone resistance in CGA has occurred.
The four largest clones among the quinolone resistant
isolates, clones 1, 2 (CGA, discussed above), 3 and 5belonged to the uropathogenic phylogenetic groups B2
and D and comprised 25% of the quinolone-resistant iso-
lates. The twelve clone 1 isolates belonged to phylogenetic
group B2. Four of these isolates were epidemiologically
associated. Clone 3 (7 isolates) belonged to phylogroup
Figure 3 Distribution of phylogenetic groups A, B1, B2 and D among clonal and singleton isolates.
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B2. Clones 1, 2 (CGA) and 3 were also present among
fluoroquinolone resistant isolates from 2003 [8]. The clones
did not display uniform resistance patterns, although
all of clone 3 and 66% of clone 2 (CGA) isolates were
trimethoprim-sulfonamide resistant.
Quinolone resistance was positively correlated with
phylogenetic group D and negatively correlated with phylo-
genetic group B2 as has previously been reported [27-29].
This correlation was confined to non-clonal isolates,
which implies that phylogroup D more readily acquires
quinolone resistance mutations than phylogroup B2
and that the spread of clones is of lesser importance, in
contrast to what has previously been suggested [8,14].
The predominant multiresistance phenotype, resistance
to ampicillin, sulphonamide, trimethoprim, tetracycline
and chloramphenicol was found in 19% of quinolone
resistant isolates. It was widely disseminated among
clonally unrelated isolates. This resembles the resistance
pattern described in outbreak strains of O15:K52:H1 and
CGA [16,17] and was found in three of the CGA isolatesFigure 4 Distribution of clonal and singleton isolates among
cipro0.032, cipro0.5 and cipro64 isolates.in this study. The genes giving this resistance phenotype
have been located in a chromosomal integration hot spot
in CGA by Lescat and coworkers [30].
This multiresistance pattern is one typically associated
with transposable elements and plasmids, suggesting an
association between quinolone resistance and mobile
genetic elements and lending support to the idea that
multiresistance arises by the mobilization of transposable
elements caused by induction of the SOS response during
quinolone therapy, an effect that has been suggested by
several authors [22-24]. In this model, it is exposure to
quinolones that causes mobilization of multiresistance
elements, which is consistent with an early emergence
of multiresistance, as observed in this study.
Fluoroquinolones are popular antibiotics; easily admin-
istered, cheap, broadly applicable, quick acting and show-
ing low toxicity. However, in view of the emergence of
resistance in pathogenic clonal groups such as CGA and
the tendency of fluoroquinolones to provoke multiresis-
tance, some caution in their use and monitoring of their
effects is indicated.Figure 5 Distribution of phylogenetic groups among cipro0.032,
cipro0.5 and cipro64 isolates.
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This study supports earlier findings of association
between ciprofloxacin resistance and resistance to
other antibiotics. We found that emergence of multi-
resistance arises early in the development of quin-
olone resistance and is mostly associated with
singleton isolates. This is consistent with exposure to
quinolones causing quinolone resistance by mutations
and mobilization of multiresistance elements by in-
duction of the SOS response. The spread of clones
seems to be less important than previously reported




E. coli isolates were collected from community urine
samples submitted to Telelab, a microbiology laboratory
serving hospitals and primary practices in the counties
of Telemark and Vestfold, south-eastern Norway for
routine bacteriological analysis and showing significant
bacteruria (pure culture of ≥ 10 000 bacteria/ml). The
material consisted of 150 consecutive nalidixic acid re-
sistant isolates and 43 randomly-chosen nalidixic acid
sensitive isolates collected in the same period in 2005.
E. coli was identified by colony morphology and bio-
chemical profile using the three tube test [31].
Clonal analysis
Pulsed-field gel electrophoresis using restriction
endonuclease XbaI was performed as previously de-
scribed [8,32]. Gels were photographed, scanned as
TIFF files, and imported into Gelcompar software
(Applied Maths, Sint-Martin-Latem, Belgium). A den-
drogram was constructed using band-based comparisons
with Dice coefficient and cluster analysis with the un-
weighted pair-group method with arithmetic average
(UPGMA); 1% position tolerance and 3% optimization set-
tings were used. PFGE patterns differing by less than
seven bands from prototype members were assigned to
the same clone.
Phylogrouping
Phylogrouping by triplex-PCR was performed as previously
described [8,32].
Resistance
MICs of ampicillin, mecillinam, nitrofurantoin, sulpho-
namide, trimethoprim, tetracycline, nalidixic acid, ciproflox-
acin, kanamycin and chloramphenicol were measured by
agar dilution on iso-sensitest medium (Oxoid, Basingstoke,
UK). MIC was defined as the lowest concentration that
completely inhibited growth.Clonal group A
Isolates were identified by detection of the fumC SNP
C288T by PCR as previously described [18,20].
Statistical analyses
The Pearson Chi-square test was used to detect significant
differences in clonality and phylogenetic distribution
between nalidixic acid resistant and sensitive isolates.
The t-test was used to test for significant difference in
multiplicity of antibiotic resistances. The z-test was
used to compare proportions.
Competing interests
The authors report no competing interest.
Authors’ contributions
Phylogrouping was done by IHH and AGA. PFGE was done by IHH. CGA
testing was done by AGA and IHH. Antibiotic resistance testing was
conducted by IHH. The study was planned by BEK, NG, AJ and LS. Data
analysis, statistical analysis and drafting of the manuscript were done by LS
with the assistance of AJ. NG and BEK provided critical comments on the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the Scandinavian Society for
Antimicrobial Chemotherapy and Norsk Overvåkingssystem for
Antibiotikaresistente Mikrober (NORM), tax relief via the Skattefunn system
and Telelab's internal funds.
Author details
1Unilabs Telelab, Skien, Norway. 2Department of Environmental and Health
Sciences, Telemark University College, Bø, Norway. 3Department of
Microbiology and Virology, University of Tromsø, Tromsø, Norway. 4Present
address: Telemark Hospital, Medical and Environmental Genetics Unit, Skien,
Norway. 5Present address: Department of Medical Microbiology, Vestfold
Trust Hospital, Tønsberg, Norway.
Received: 26 January 2014 Accepted: 28 May 2014
Published: 19 June 2014
References
1. Antimicrobial resistance interactive database, EARS-Net. [http://www.
ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/
database.aspx]
2. Heisig P: Genetic evidence for a role of parC mutations in development
of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob
Agents Chemother 1996, 40:879–885.
3. Hopkins KL, Davies RH, Threlfall EJ: Mechanisms of quinolone resistance in
Escherichia coli and Salmonella: recent developments. Int J Antimicrob
Agents 2005, 25:358–373.
4. Jacoby GA: Mechanisms of resistance to quinolones. Clin Infect Dis 2005,
41(Suppl 2):120–126.
5. Perichon B, Courvalin P, Galimand M: Transferable resistance to
aminoglycosides by methylation of G1405 in 16S rRNA and to
hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Antimicrob Agents Chemother 2007, 51:2464–2469.
6. Piddock LJ: Clinically relevant chromosomally encoded multidrug
resistance efflux pumps in bacteria. Clin Microbiol Rev 2006,
19:382–402.
7. Robicsek A, Jacoby GA, Hooper DC: The worldwide emergence of
plasmid-mediated quinolone resistance. Lancet Infect Dis 2006,
6:629–640.
8. Grude N, Strand L, Mykland H, Nowrouzian FL, Nyhus J, Jenkins A, Kristiansen
B-E: Fluoroquinolone-resistant uropathogenic Escherichia coli in Norway:
evidence of clonal spread. Clin Microbiol Infect 2008, 14:498–500.
9. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG:
Fluoroquinolone-resistant urinary isolates of Escherichia coli from
outpatients are frequently multidrug resistant: results from the North
Strand et al. BMC Research Notes 2014, 7:376 Page 8 of 8
http://www.biomedcentral.com/1756-0500/7/376American urinary tract infection collaborative alliance-quinolone resist-
ance study. Antimicrob Agents Chemother 2006, 50:2251–2254.
10. Ruiz del Castillo B, Vinué L, Román EJ, Guerra B, Carattoli A, Torres C, Martinez-
Martinez L: Molecular characterization of multiresistant Escherichia coli
producing or not extended-spectrum β-lactamases. BMC Microbiol 2013, 13:84.
11. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, ZhanelL GG:
Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-
resistant urinary tract infections in Canada, 2002 to 2004.
Antimicrob Agents Chemother 2009, 53:2733–2739.
12. Platell JL, Johnson JR, Cobbold RN, Trott DJ: Multidrug-resistant
extraintestinal pathogenic Escherichia coli of sequence type ST131 in
animals and food. Vetmic 2011, 153:99–108.
13. Giufre M, Graziani C, Accogli M, Luzzi I, Busani L, Cerquetti M, on behalf of
the Escherichia coli Study Group: Escherichia coli of human and avian
origi: detection of clonal groups associated with fluoroquinolone and
multidrug resistance in Italy. J Antimicrob Chemother 2012, 67:860–867.
14. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A: European
emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:
H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated
cystitis. J Clin Microbiol 2008, 46:2605–2612.
15. Manges AR, Johnson JR, Foxman B, O’Bryan TT, Fullerton KE, Riley LW:
Widespread distribution of urinary tract infections caused by a multidrug-
resistant Escherichia coli clonal group. N Engl J Med 2001, 345:1007–1013.
16. Manges AR, Dietrich PS, Riley LW: Multidrug-resistant Escherichia coli
clonal groups causing community-acquired pyelonephritis. Clin Infect Dis
2004, 38:329–334.
17. Johnson JR, Manges AR, O’Bryan TT, Riley LW: A disseminated multidrug-
resistant clonal group of uropathogenic Escherichia coli in pyelonephritis.
Lancet 2002, 359:2249–2251.
18. Johnson JR, Owens K, Manges AR, Riley LW: Rapid and specific detection
of Escherichia coli clonal group A by gene-specific PCR. J Clin Microbiol
2004, 42:2618–2622.
19. Johnson JR, Murray AC, Kuskowski MA, Schubert S, Prére M-F, Picard B,
Colodner R, Raz R, and the Trans-Global Initiative for Antimicrobial Resistance
Analysis (TIARA) Investigators: Distribution and characteristics of Escherichia
coli clonal group A. Emerg Infect Dis 2005, 11:141–145.
20. Strand L, Jenkins A, Grude N, Allum A-G, Mykland H-C, Nowrouzian FL,
Kristiansen B-E: Emergence of fluoroquinolone-resistant clonal group A: clonal
analysis of Norwegian and Russian E. coli isolates. APMIS 2010, 118:571–577.
21. Johnson JR, Kuskowski MA, Menard M, Gajewski A, Xercavins M, Garau J:
Similarity between human and chicken Escherichia coli isolates in
relation to ciprofloxacin resistance status. J Infect Dis 2006, 194:71–78.
22. Walsh TR: Combinatorial genetic evolution of multiresistance.
Curr Opin Microbiol 2006, 9:476–482.
23. Guerin E, Cambray G, Sanchez-Alberola N, Campoy S, Erill I, Da Re S,
Gonzalez-Zorn B, Barbé J, Ploy M-C, Mazel D: The SOS response controls
integron recombination. Science 2009, 324:1034.
24. Beaber JW, Hochhut B, Waldor MK: SOS response promotes horizontal
dissemination of antibiotic resistance genes. Nature 2004, 427:72–74.
25. AFA: http://www.unn.no/afa/category10274.html (2009).
26. AFA: http://www.unn.no/afa/category10274.html (2007).
27. Johnson JR, Van Der Schee C, Kuskowski MA, Goessens W, Van Belkum A:
Phylogenetic background and virulence profiles of fluoroquinolone-
resistant clinical Escherichia coli isolates from the Netherlands. J Infect Dis
2002, 186:1852–1856.
28. Johnson JR, Kuskowski MA, O’Bryan TT, Colodner R, Raz R: Virulence genotype
and phylogenetic origin in relation to antibiotic resistance profile among
Escherichia coli urine sample isolates from Israeli women with acute
uncomplicated cystitis. Antimicrob Agents Chemother 2005, 49:26–31.
29. Moreno E, Prats G, Sabate M, Perez T, Johnson JR, Andreu A: Quinolone,
fluoroquinolone and trimethoprim/sulfamethoxazole resistance in
relation to virulence determinants and phylogenetic background among
uropathogenic Escherichia coli. J Antimicrob Chemother 2006, 57:204–211.
30. Lescat M, Calteau A, Hoede C, Barbe V, Touchon M, Rocha E, Tenaillon O,
Médigue C, Johnson JR, Denamur E: A module located at a chromosomal
integration hot spot is responsible for the multidrug resistance of a
reference strain from Escherichia coli clonal group A. Antimicrob Agents
Chemother 2009, 53:2283–2288.31. Lassen J: Rapid identification of gram-negative rods using a three-tube
method combined with a dichotomic key. Acta Pathol Microbiol Scand
Suppl 1975, 83:525–533.
32. Grude N, Potaturkina-Nesterova NI, Jenkins A, Strand L, Nowrouzian FL, Nyhus
J, Kristiansen B-E: A comparison of phylogenetic group, virulence factors
and antibiotic resistance in Russian and Norwegian isolates of Escherichia
coli from urinary tract infection. Clin Microbiol Infect 2007, 13:208–211.
doi:10.1186/1756-0500-7-376
Cite this article as: Strand et al.: High levels of multiresistance in quinolone
resistant urinary tract isolates of Escherichia coli from Norway; a non clonal
phenomen? BMC Research Notes 2014 7:376.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
